Geoffrey W McCaughan1. 1. The AW Morrow Gastroenterology and Liver Centre, The Centenary Research Institute, Royal Prince Alfred Hospital and The University of Sydney, Missenden Road, Camperdown, NSW, 2050, Australia. g.mccaughan@centenary.usyd.edu.au.
Abstract
BACKGROUND: Twenty years ago, liver transplantation for hepatitis B had been a relative contraindication to universal HBV recurrence and poor outcomes. Over the ensuing two decades, there has been refinement of prevention strategies in order to minimize HBV recurrence in the allograft. RESULTS: Currently, the most efficacious and cost-effective strategies include newer oral antiviral drugs in combination with low doses of hepatitis B immunoglobulin (HBIG). More recently, strategies have been successful in withdrawing HBIG and newer approaches of HBIG avoidance are currently under development. CONCLUSION: Thus, 20 years afterward, HBV recurrence is <5% and outcomes following liver transplantation are excellent.
BACKGROUND: Twenty years ago, liver transplantation for hepatitis B had been a relative contraindication to universal HBV recurrence and poor outcomes. Over the ensuing two decades, there has been refinement of prevention strategies in order to minimize HBV recurrence in the allograft. RESULTS: Currently, the most efficacious and cost-effective strategies include newer oral antiviral drugs in combination with low doses of hepatitis B immunoglobulin (HBIG). More recently, strategies have been successful in withdrawing HBIG and newer approaches of HBIG avoidance are currently under development. CONCLUSION: Thus, 20 years afterward, HBV recurrence is <5% and outcomes following liver transplantation are excellent.
Authors: D Mutimer; D Pillay; E Dragon; H Tang; M Ahmed; K O'Donnell; J Shaw; N Burroughs; D Rand; P Cane; B Martin; S Buchan; E Boxall; S Barmat; K Gutekunst; P McMaster; E Elias Journal: J Hepatol Date: 1999-04 Impact factor: 25.083
Authors: A Marzano; M Salizzoni; W Debernardi-Venon; A Smedile; A Franchello; A Ciancio; E Gentilcore; P Piantino; A M Barbui; E David; F Negro; M Rizzetto Journal: J Hepatol Date: 2001-06 Impact factor: 25.083
Authors: Christian M Lange; Jörg Bojunga; Wolf Peter Hofmann; Katrin Wunder; Ulrike Mihm; Stefan Zeuzem; Christoph Sarrazin Journal: Hepatology Date: 2009-12 Impact factor: 17.425
Authors: Eugene R Schiff; Ching-Lung Lai; Stefanos Hadziyannis; Peter Neuhaus; Norah Terrault; Massimo Colombo; Hans L Tillmann; Didier Samuel; Stefan Zeuzem; Leslie Lilly; Maria Rendina; Jean-Pierre Villeneuve; Nicole Lama; Craig James; Michael S Wulfsohn; Hamid Namini; Christopher Westland; Shelly Xiong; Gavin S Choy; Sally Van Doren; John Fry; Carol L Brosgart Journal: Hepatology Date: 2003-12 Impact factor: 17.425